Dallas, Texas (PRWEB) August 12, 2013
Colorectal cancer (CRC) is the third most commonly diagnosed cancer, and the second most common cause of mortality amongst cancer patients. The prognosis is directly related to early diagnosis, with survival rates dramatically improved by early diagnosis and treatment. Thanks to the introduction of CRC screening programs, mortality in the developed countries is falling; however incidence continues to rise as a result of diet and increasingly sedentary lifestyles. While historically, colorectal cancer incidence in the developing world is low, in recent years, disease diagnosis rates have dramatically increased, as a result of changing lifestyles, awareness and improved access to medical services. CRC screening can improve survival rates, and reduce the overall cost of patient treatment.
Questions Answered in this Report:
Colorectal cancer can be caused by somatic mutations as well as inherited mutations. These mutations lead to changes in the colon that can be detected by detection of bleeding. But many of these mutations can also be detected by genetic and other tests. How quickly will new gene tests be adopted by the CRC screening market?
What are the key differences in CRC screening carried out in different countries, and how will these differences affect adoption of new screening tests?
Existing CRC screening is based on inexpensive, but inaccurate stool analysis tests, or expensive but accurate endoscopies. The first DNA screening tests are expected to come to market in 2014, from Exact Sciences and EpiGenomics. Which new DNA-based screening test will win out?
In-vitro CRC screening is a fast evolving technological area. How will changes in technology affect sales of existing CRC screening tests? Who are the new players in CRC screening? How will patient attitudes affect the In-vitro CRC screening test market?
Major Company Profiles:
1 Abbott Molecular
3 Beckman Coulter
4 Biomarcare Technologies
5 Companion Dx
6 Eiken Chemical
8 Exact Sciences
10 Fujirebio (Miraca Holdings)
14 Kyowa Medex
15 MDx Health (was OncoMethylome)
16 Merck Millipore
18 Mode Diagnostics
19 Oncocyte (Bio Time)
20 Quest Diagnostics
22 Randox Laboratories
23 Schebo Biotech
24 SciMarket Technologies
25 Siemens Healthcare
26 Signature Diagnostics
28 Veda Lab
Purchase a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=110513.
Browse more reports on Cancer Diagnostics Market @ http://www.rnrmarketresearch.com/reports/life-sciences/diagnostics/in-vitro-diagnostics-ivd/cancer-diagnostics.
RnRMarketResearch.com is an online database of market research reports offers in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.